Fortbildungsveranstaltung Ablative Tumortherapie

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive diagnosis and treatment of cancer and peripheral vascular disease.

The Company was founded in Queensbury in 1988 and has grown into a NASDAQ-listed public company with a total market capitalization of more than $400 million. AngioDynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, selling its products in the US through a direct sales force and in international markets through a combination of direct sales and distributors.

The Company’s achievements have attracted the attention of the national financial community and media, alike. In 2006, AngioDynamics was named to Business Week’s list of Hot Growth Companies. The same year, the Company received Forbes recognition as one of the 200 Best Small Companies in America. AngioDynamics was number 11 on this prestigious list and was also recognized as one of the best newcomers to Forbes’ annual publication of company results.

Capitalizing on its success, in January 2007, AngioDynamics entered the growing interventional oncology market through its $220 million acquisition of RITA Medical Systems.

With the addition of RITA’s complementary products to its existing market basket, AngioDynamics now boasts a diverse product line that includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

Over the years, one of the distinguishing characteristics of AngioDynamics has been the Company’s consistent ability to successfully develop and bring to market new technologies and products. For example, during the recent fiscal second quarter 2008 approximately 50% of AngioDynamics’ sales were generated from new products introduced over the last five years. And over half of the Company’s growth was attributed to new products introduced during the last fiscal year.

AngioDynamics believes it is well-poised to continue that trend. Looking into the future, the Company plans to bring forth a continuing stream of innovations that greatly improve patient care by providing the highest quality, best performing products.